Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update
November 4, 2019 7:00 AM ESTJeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019
J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue
Jeuveau® Achieved Number Three Unit Share Position in the U.S. for Q3 20191
Nuceiva Approved in the European Union and Launched in Canada
NEWPORT BEACH, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today... More
